

Complete Manuscript Title:

Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms

Short Running Head:

COVID-19 Vaccines and Otologic Symptoms

Authors:

Ramsi A. Woodcock, JD, MSc*
Assistant Professor
University of Kentucky Rosenberg College of Law
Secondary Appointment
Department of Management
University of Kentucky Gatton College of Business & Economics
Law Building
620 S. Limestone
Lexington, KY 40506
United States of America
Office Phone: +1-859-257-1253
Cell Phone (preferred): +1-646-385-3592
Email: rwo236@uky.edu

Loren J. Bartels MD, FACS**
Director, Tampa Bay Hearing and Balance Center
Clinical Professor of Otolaryngology
University of South Florida College of Medicine
5 Tampa General Circle 610
Tampa, FL 33606
United States of America
Office Phone: +1-813-315-4327
Email: lbartels@tampabayhearing.com

Sources of Support/Disclosure of Funding:

This study received no outside support or funding.

Conflicts of Interest:

Ramsi A. Woodcock suffers from otologic symptoms that he believes to have been caused by COVID-19 vaccination. He is Loren J. Bartels' patient.

*Contribution: conceptualization; data curation; formal analysis; investigation; methodology; project administration; resources; software; supervision; validation; visualization; writing—original draft; writing—review & editing. *This author is not a medical doctor. His contributions to this paper are not intended to be, nor should they be taken as, medical advice.*

**Contribution: methodology; writing—review & editing.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

COVID-19 Vaccines and Otologic Symptoms

1 ABSTRACT

2 **Hypothesis:** This study investigates whether U.S. Centers for Disease Control and Prevention
3 Vaccine Adverse Events Reporting System (VAERS) data suggest an association between
4 vertigo, tinnitus, hearing loss, Bell's palsy and the COVID-19 vaccines administered in the
5 United States.

6 **Background:** Published case reports suggest a possible association between various otologic
7 symptoms and the COVID-19 vaccines, but the only published analysis of VAERS data, which
8 did not account for underreporting of late-appearing adverse events, found no association
9 between hearing loss and the vaccines.

10 **Methods:** The incidence in VAERS of vertigo, tinnitus, hearing loss, and Bell's palsy associated
11 with COVID-19 vaccinations administered between December 14, 2020 and June 7, 2021 was
12 compared with published rates for the general population. To account for underreporting of late-
13 appearing adverse events, incidences were calculated using only the initial part of the
14 observation period, during which reported events spike above expected events.

15 **Results:** The COVID-19 vaccines were associated with statistically significant increases in the
16 incidence of vertigo, tinnitus, hearing loss, and Bell's palsy of 1877, 50, 12, and 14 cases per
17 100,000, respectively. In relation to the mRNA-1273 or BNT162b2 vaccines, the Ad26.COV2.S
18 vaccine was associated with a statistically significant excess incidence of vertigo, tinnitus, and
19 hearing loss of at least 723, 57, and 55 cases per 100,000, respectively.

20 **Conclusion:** These results suggest an association between the COVID-19 vaccines and vertigo,
21 tinnitus, hearing loss, and Bell's palsy. They also suggest that, with respect to vertigo, tinnitus,
22 and hearing loss, the association is relatively strong for the Ad26.COV2.S vaccine.

COVID-19 Vaccines and Otologic Symptoms

23

I. INTRODUCTION

24 Published case reports suggest a possible association between the COVID-19 vaccines and
25 various otologic symptoms, including hearing loss, tinnitus, and vertigo.¹⁻³ However, the only
26 preliminary study of otologic symptoms in U.S. Centers for Disease Control and Prevention
27 Vaccine Adverse Event Reporting System (VAERS) data published to date, in which Formeister
28 et al. investigated reports of hearing loss, failed to find an association.^{4,5} This may be because
29 vaccine adverse event reports relate to a single trigger—vaccination—whereas the population
30 incidence rates to which they must be compared relate to multiple triggers.⁶ For example, the
31 population incidence of vertigo includes cases of vertigo due to trauma, viral infection, and genetic
32 disorders, among other things, whereas doctors and patients likely tend to report to VAERS only
33 cases of vertigo that they believe to be triggered by vaccination. As a result, the incidence rate of
34 vertigo in the VAERS reports will be lower than the population incidence rate unless vaccination
35 triggers more vertigo than all other triggers combined.

36 The U.S. Centers for Disease Control and Prevention (CDC) tries to address this problem by
37 encouraging doctors and patients to report all symptoms they encounter after vaccination.⁷ In
38 theory, that should ensure that symptoms due to all triggers, including vaccination, are reported,
39 with the result that, if vaccination triggers additional cases of a particular symptom, then the
40 incidence rate in the VAERS reports will be higher than the population incidence rate and
41 researchers will be able to infer from this difference that there is an association between the
42 symptom and vaccination.

43 Unfortunately, doctors and patients do not heed the CDC. As Figure 1 shows, VAERS reports
44 for all vaccines, COVID or otherwise, decline dramatically as the date of onset of the reported

COVID-19 Vaccines and Otologic Symptoms

45 symptom extends beyond the vaccination date. If doctors and patients were to report all symptoms
46 based on all triggers, including post-vaccination triggers, one would expect the line to be
47 approximately flat, unless vaccination is a disproportionate source of all symptoms experienced
48 by the population due to any cause, which is unlikely. In the absence of any test enabling doctors
49 and patients to determine whether a particular symptom is caused by vaccination, doctors and
50 patients rely on proximity of the date of symptom onset to the date of vaccination as a proxy for
51 causation, which explains why, in Figure 1, reports spike for symptoms with onset immediately
52 after vaccination and then fall off almost to zero after a few weeks.⁸ As shown in Figure 3, VAERS
53 reports for the symptoms considered in this study—vertigo, tinnitus, hearing loss, and Bell’s
54 palsy—all exhibit a similar initial spike in reported symptoms with onset immediately after
55 vaccination, followed by a precipitous decline in reported symptoms as the date of onset moves
56 farther away from the date of vaccination.

57 One way around the failure of doctors and patients fully to report symptoms due to non-
58 vaccine triggers would be to use published reporting sensitivity rates to inflate the raw number of
59 VAERS reports. Unfortunately, existing studies of VAERS reporting sensitivity, such as that of
60 Miller et al., are based on VAERS reports that have been selected for their temporal proximity to
61 vaccination—the same filter that doctors and patients place on their own reporting—and hence
62 are unlikely fully to capture underreporting of symptoms associated with non-vaccine triggers.⁹
63 Sensitivity rates extrapolated from a comparison with clinical trial adverse event reports suffer
64 from a similar limitation, because clinical trials solicit reports only within a few days of
65 vaccination.

66 Fortunately, there is another way around the underreporting of non-vaccine-triggered events.

COVID-19 Vaccines and Otologic Symptoms

67 If the number of cases reported during the peak reporting period immediately after vaccination—
68 the “spike period”—exceeds the number of cases expected during that period based on the
69 population incidence rate of the symptom, then it follows that the vaccine is a trigger of the
70 symptom, even if reported cases fall below expected cases for the rest of the observation period,
71 and even if the incidence rate implied by the reports, if calculated over the entire observation
72 period, is below the population incidence rate. For the only way in which reported cases can
73 exceed expected cases during any part of an observation period, despite underreporting of cases
74 due to non-vaccine triggers, is if vaccine-triggered cases of the symptom are numerous enough
75 over that period to make up the difference. But the existence of any number of vaccine-triggered
76 cases, if statistically significant in magnitude, is sufficient to establish an association between the
77 vaccine and the symptom.

78 Consider a numerical illustration. Suppose that vaccination triggers one hundred excess cases
79 of vertigo in the first day after vaccination and none on the second day, and that all other triggers
80 cause an additional hundred cases every day, but that doctors and patients, despite reporting all
81 symptoms on the first day regardless of trigger, report none on the second day, because they
82 assume that none of the day-two symptoms are triggered by the vaccine. If 365,000,000
83 vaccinations are observed, then for a 2-day observation period, the incidence of vertigo is 10 (per
84 100,000 person-years, as with all incidence rates discussed in the present study), but the population
85 incidence (which is based on the number of cases caused by all other triggers) is 15, suggesting,
86 falsely, that there is no association between vaccination and the symptom. If, however, one
87 considers only the first day, during which total reported cases of 200 spike above expected cases
88 of 100, then the incidence is 20, which exceeds the population incidence of 15 and therefore

COVID-19 Vaccines and Otologic Symptoms

89 correctly indicates the existence of an association.

90 An additional consideration complicates analysis of spike periods: reports may not be
91 accurate. As a result, the presence of a spike in raw report numbers for a particular symptom is
92 not sufficient to suggest the existence of an association between the vaccine and the symptom.
93 The spike must be discounted, either through examination of individual reports or by a rate of
94 accuracy derived from analysis of past reports. Even if discounting eliminates the spike, however,
95 the analysis does not end, because the studies, such as that of Miller et al., that provide sensitivity
96 rates for reporting of adverse events with onset close to the date of vaccination are likely to capture
97 underreporting during spike periods even if they do not capture underreporting of cases
98 thereafter.⁹ The same is true for sensitivity rates extrapolated from a comparison with clinical trial
99 reports. Published sensitivity rates and those extrapolated from clinical trials can therefore be used
100 to offset the accuracy discount with a multiplier that accounts for underreporting during the spike.

101 II. MATERIALS & METHODS

102 To investigate the relationship between the COVID vaccines administered in the United States
103 (Moderna's mRNA-1273, Pfizer-BioNTech's BNT162b2, and Johnson & Johnson's
104 Ad26.COV2.S) and otologic symptoms, analysis of spikes in reports to VAERS of vertigo,
105 tinnitus, hearing loss, and Bell's palsy over expected levels were carried out. To avoid bias
106 associated with the ongoing arrival of new reports regarding the COVID-19 vaccines, the analysis
107 was limited to vaccines administered between December 14, 2020 and June 7, 2021, to symptoms
108 with an onset within 30 days of vaccination, and to reports made within 60 days of vaccination.
109 The MedDRA-coded symptom fields in the VAERS database were searched for "vertigo,"
110 "tinnitus," "hearing loss," "bell's palsy," and synonyms, and the results filtered for the

COVID-19 Vaccines and Otologic Symptoms

111 “COVID19” vaccine type to create datasets for each symptom. Table 1 and Figure 2 provide more
112 information on the search terms, datasets, and study parameters.

113 Formeister et al. manually reviewed each VAERS adverse event report in their study sample
114 for accuracy. For the present study of multiple symptoms relating to nearly seven months of
115 vaccinations, as opposed to the study of a single symptom over 2.5 months carried out by
116 Formeister et al., manual verification could not be undertaken. Instead, a best-guess accuracy rate
117 was identified by running the same search of the VAERS data for hearing loss reported by
118 Formeister et al. and using the resulting case count of 475 to extrapolate an accuracy rate of 8%
119 from Formeister et al.’s conclusion that only 40 reported cases in their VAERS data were accurate.
120 This appears to be a very low accuracy rate. By contrast, an accuracy rate of 57% is implied by
121 the work of Su et al. on anaphylaxis reports to VAERS in relation to a number of non-COVID-19
122 vaccines.¹⁰

123 A reporting sensitivity rate of 30%, corresponding to a multiplier of 3.3, was used for tinnitus,
124 hearing loss, and Bell’s palsy. This rate was obtained by averaging the rates reported by Miller et
125 al. for reports of anaphylaxis and Guillain-Barré syndrome associated with non-COVID-19
126 vaccinations.⁹ It is somewhat lower than the 50% sensitivity rate that appears to have been
127 arbitrarily chosen for sensitivity testing of hearing loss reports by Formeister et al.

128 A much lower sensitivity rate—0.6%, corresponding to a multiplier of 166.9—was used for
129 vertigo, because, as Neuhauser has pointed out, vertigo is common in the general population,
130 affecting between 20% and 30% of adults.¹¹ Doctors and patients may therefore be less likely to
131 report vertigo in connection with the COVID-19 vaccines than they are to report tinnitus, hearing
132 loss, or Bell’s palsy, each of which is rare in comparison.¹¹ To identify an appropriate reporting

COVID-19 Vaccines and Otologic Symptoms

133 sensitivity rate for vertigo, the incidence of other common symptoms—pain, erythema, swelling,
134 fever, headache, fatigue, myalgia, and nausea or vomiting—reported in the COVID-19 vaccines’
135 Phase III clinical trials was compared with the incidence of the same symptoms in the VAERS
136 reports and the largest result—that for fever—was used to obtain the 0.6% reporting sensitivity
137 rate.^{12–14} A comparison with clinical trial reports was considered probative of the true reporting
138 sensitivity rate during the spike period because clinical trial administrators solicit reports from
139 trial subjects within seven days of vaccination.^{12–14}

140 Spike periods were determined after application of the 8% accuracy discount and the
141 applicable underreporting multiplier to the VAERS report counts for each symptom. As shown in
142 Figure 3 and discussed more fully in the Results section, the spike period was two days each for
143 vertigo, tinnitus, and Bell’s palsy, and one day for hearing loss. The statistical significance of the
144 incidence rate of each symptom over its spike period, in relation to the published population
145 incidence rate for the symptom, was determined using the normal approximation to the binomial
146 distribution for one-sample inference with two tails.^{15–18}

147 The proportional reporting ratio (PRR),¹⁹ which compares the incidence rate of symptoms in
148 reports related to the vaccine at issue (here, the COVID-19 vaccines) to the rate of all other
149 symptoms in all other VAERS reports,²⁰ was also calculated for all four symptoms. The PRR has
150 two helpful features. First, it compares VAERS data with other VAERS data, so the problem of
151 comparing single-trigger VAERS incidence rates to multiple-trigger population incidence rates is
152 avoided. Second, the PRR provides a useful check on the appropriateness of the accuracy and
153 reporting sensitivity rates used in the present study, because, if accuracy and reporting sensitivity
154 rates are constant across all vaccines, then these rates cancel out of the PRR, making the PRR

COVID-19 Vaccines and Otologic Symptoms

155 invariant in reporting accuracy and sensitivity assumptions. The statistical significance of the
156 PRRs, in relation to the null hypothesis of one (i.e. that there is no difference between the
157 incidence of the symptom in COVID-19 vaccine reports and the incidence of all other symptoms
158 in all other vaccine reports) was determined using the chi-squared test with one degree of freedom.

159 Finally, to investigate the relative association of different COVID-19 vaccines with vertigo,
160 tinnitus, hearing loss, and Bell's palsy, VAERS spike-period case counts, discounted as above,
161 were categorized by vaccine manufacturer, incidence rates for each were calculated using CDC
162 data on total administered vaccine doses per manufacturer, and, for each symptom, the normal
163 approximation to the binomial distribution for two-sample inference was applied with two tails.
164 For all three tests, p-values below 0.05 were considered significant.

165 University of Kentucky determined that this study is exempt from institutional review board
166 approval because the study uses deidentified data publicly available on the CDC website.

167 III. RESULTS

168 Figure 3 shows the distribution of cases, after adjustment for accuracy and underreporting, in
169 terms of time to symptom onset, including the spike period for each symptom. The incidence rate
170 of vertigo in the VAERS reports over vertigo's two-day spike period was 3,277 (per 100,000
171 person-years, as for all incidence rates reported here), significantly in excess of the population
172 incidence of vertigo of 1,400 reported by Neuhauser et al. ($p < 0.00001$).¹⁷ The incidence rate of
173 tinnitus in the VAERS reports over tinnitus's two-day spike period was 104, significantly in
174 excess of the population incidence of tinnitus of 54 reported by Martinez et al. ($p < 0.00001$).¹⁶
175 The incidence rate of hearing loss in the VAERS reports over hearing loss's one-day spike period
176 was 39, significantly in excess of the population incidence of hearing loss of 27 reported by

COVID-19 Vaccines and Otologic Symptoms

177 Alexander et al. ($p < 0.00001$).¹⁸ The incidence rate of Bell's palsy in the VAERS reports over
178 Bell's palsy's two-day spike period was 37, significantly in excess of 23, which is the average of
179 the population incidence rates for Bell's palsy referenced by Ozonoff et al. ($p < 0.00001$).¹⁵ As
180 Table 2, which reports these results, shows, incidence rates calculated using the three-week
181 observation period employed by Formeister et al., rather than the spike periods, were, by contrast,
182 all lower than their respective population incidence rates, by 846 for vertigo, 36 for tinnitus, 22
183 for hearing loss, and 14 for Bell's palsy. Incidence rates in the VAERS reports break even with
184 population incidence rates at approximately a one-week observation period.

185 The results for vertigo and tinnitus were robust to lower underreporting multipliers. As Table
186 2 also reports, a statistically significant excess incidence of tinnitus remained after reduction of
187 the underreporting multiplier from 3.3 to the value of 2 used by Formeister et al., and a statistically
188 significant excess incidence of vertigo remained after the underreporting multiplier was scaled
189 down in the same proportion (i.e., by the ratio of 2 to 3.3).

190 The PRRs, which require no assumption regarding the rate of accuracy or the rate of reporting
191 sensitivity, were, for vertigo, tinnitus, hearing loss, and Bell's palsy, 4.76, 5.41, 2.63, and 1.46,
192 respectively, as shown in Table 3. Those for vertigo and tinnitus exceeded the null hypothesis of
193 one to a statistically significant degree ($p < 0.001$ for vertigo and $p < 0.0001$ for tinnitus). This
194 result was consistent with the robustness of the spike period results for vertigo and tinnitus.

195 These results were clinically significant. As Table 2 shows, over the course of the two-day
196 spike period after vaccination, 30,761 of the 171 million people who received at least one dose of
197 vaccine in the United States during the study period (about 1 per 5,569 persons receiving at least
198 one dose) are estimated to have had vertigo. That was 17,619 more cases than the 13,142 cases

COVID-19 Vaccines and Otologic Symptoms

199 that were expected over that period based on the population incidence of vertigo (an excess rate
200 of 1 per 9,723 persons receiving at least one dose). For tinnitus, the excess of reported cases over
201 expected cases over the two-day tinnitus spike period was 466 (an excess rate of 1 per 367,579
202 persons receiving at least one dose). For hearing loss, it was 58 excess cases over the one-day
203 hearing loss spike period (about 1 per 2.94 million persons receiving at least one dose), and for
204 Bell's palsy it was 130 excess cases over the two-day Bell's palsy spike period (about 1 extra
205 Bell's palsy case per 1.32 million persons receiving at least one dose).

206 Table 4 sets forth the results regarding the relative associations of the three vaccines
207 administered in the United States. The incidence of vertigo associated with the Ad26.COV2.S
208 vaccine in the VAERS reports was 4,258, in excess of the incidence of 3,535 associated with the
209 mRNA-1273 vaccine and the incidence of 2,947 associated with the BNT162b2 vaccine. The
210 excess in the incidence of vertigo associated with the Ad26.COV2.S vaccine in relation to both
211 the mRNA-1273 vaccine and the BNT162b2 vaccine was statistically significant ($p < 0.00001$),
212 as was the excess in the incidence of vertigo associated with the mRNA-1273 vaccine in relation
213 to the BNT162b2 vaccine ($p < 0.00001$). The incidence of tinnitus associated with the
214 Ad26.COV2.S vaccine in the VAERS reports was 157, in excess of the incidence of 100 associated
215 with both the mRNA-1273 and BNT162b2 vaccines to a statistically significant degree ($p < 0.001$
216 and $p < 0.0001$, respectively). The incidence of hearing loss associated with the Ad26.COV2.S
217 vaccine in the VAERS reports was 93, in excess of the incidences associated with the mRNA-
218 1273 and BNT162b2 vaccines of 33 and 37, respectively, to a statistically significant degree ($p <$
219 0.00001 and $p < 0.0001$, respectively). The incidence of Bell's palsy associated with the
220 BNT162b2 and mRNA-1273 vaccines in the VAERS reports was 37 for both, which exceeded the

COVID-19 Vaccines and Otologic Symptoms

221 incidence of 36 associated with the Ad26.COVS vaccine, but not to a statistically significant
222 degree.

223 These results were also clinically significant. The comparatively higher vertigo incidence rate
224 of the Ad26.COVS vaccine implies that, had the 171 million people who received at least one
225 vaccine dose over the study period all received the Ad26.COVS vaccine, rather than one of the
226 assortment of Ad26.COVS, BNT162b2, and mRNA-1273 vaccines that was actually
227 administered, there would have been 39,970 cases of vertigo over the two-day spike period, 9,209
228 more than the 30,761 cases estimated to have actually occurred (an excess rate of about 1 per
229 18,602 persons receiving at least one dose). Similarly, the vertigo incidence rate of the mRNA-
230 1273 vaccine, which was elevated relative to the vertigo incidence rate of the BNT162b2 vaccine,
231 implies that, had mRNA-1273 alone been administered, there would have been 33,183 cases of
232 vertigo over the two-day spike period, 2,422 more than the 30,761 cases estimated to have actually
233 occurred (an excess rate of about 1 per 70,733 persons receiving at least one dose). The
234 comparatively higher tinnitus incidence rate of the Ad26.COVS vaccine implies that, had
235 Ad26.COVS alone been administered, there would have been 1,471 cases of tinnitus over the
236 two-day spike period, 498 more than the 973 cases estimated to have actually occurred (an excess
237 rate of 1 per 344,028 persons receiving at least one dose). Finally, the comparatively higher
238 hearing loss incidence rate of the Ad26.COVS vaccine implies that, had Ad26.COVS alone
239 been administered, there would have been 435 cases of hearing loss over the one-day spike period,
240 250 more than the 185 cases estimated to have actually occurred (an excess rate of 1 per 684,947
241 persons receiving at least one dose).

242 IV. DISCUSSION

COVID-19 Vaccines and Otologic Symptoms

243 These results suggest a statistically significant association between the COVID-19 vaccines
244 and otologic symptoms, particularly vertigo and tinnitus, during the one-to-two-day immediate
245 post-vaccination periods over which reported cases for these symptoms spike above expected
246 cases. The results contrast with results obtained by including cases with later onset in the
247 observation period, such as those published by Formeister et al. The results also suggest that the
248 Ad26.COVS.S vaccine is more likely to trigger vertigo, tinnitus, or hearing loss than are the
249 mRNA-1273 or BNT162b2 vaccines. The number of excess cases of vertigo, tinnitus, hearing loss,
250 and Bell's palsy associated with the vaccines is quite small relative to the total number of people
251 who have received a dose of the vaccines, particularly in the case of tinnitus, hearing loss, and
252 Bell's palsy, but still clinically significant. The existence of an association over the one-to-two-
253 day spike periods does not exclude the existence of an association between the vaccines and
254 symptoms with later onset. Underreporting to VAERS prevents verification of such an association,
255 however.

256 More investigation is required to confirm these associations, because the true accuracy and
257 underreporting sensitivity rates are unknown. One reason for which the 30% sensitivity rate
258 applied for tinnitus, hearing loss, and Bell's palsy might be incorrect is that media attention paid
259 to the COVID-19 vaccines may have pushed their reporting sensitivity rates above those of the
260 vaccines considered by Miller et al., upon which the 30% rate is based.^{9,21} More investigation is
261 also required to determine the extent of recovery from the symptoms considered in the present
262 study, either to tolerability or to complete resolution, especially as there are reports of
263 improvement for some symptoms.^{2,3}

264 V. CONCLUSION

COVID-19 Vaccines and Otologic Symptoms

265 This study created a novel way to compare the incidence of post-vaccine symptoms to
266 published population incidence rates by using only cases with onset in the immediate one-to-two-
267 day post-vaccination periods during which reported cases spike above expected cases to calculate
268 incidence rates. In looking at VAERS reports of vertigo, tinnitus, hearing loss, and Bell’s palsy in
269 recipients of COVID-19 vaccines, statistical evidence of an association of the vaccines with an
270 excess of these cases appears at rates ranging from about 1 excess case per 5,500 vaccinated
271 persons to about 1 excess case per 2.94 million vaccinated persons. Variations of this methodology
272 might be helpful in investigating the risks of other vaccines.

COVID-19 Vaccines and Otologic Symptoms

273

VI. REFERENCES

- 274 1. Wichova H, Miller ME, Derebery MJ. Otologic Manifestations After COVID-19 Vaccination:
275 The House Ear Clinic Experience. *Otol Neurotol*. Published online July 9, 2021.
276 doi:10.1097/MAO.0000000000003275
- 277 2. Tseng P-T, Chen T-Y, Sun Y-S, Chen Y-W, Chen J-J. The reversible tinnitus and cochleopathy
278 followed first-dose AstraZeneca COVID-19 vaccination. *QJM*. Published online July 23,
279 2021. doi:10.1093/qjmed/hcab210
- 280 3. Parrino D, Frosolini A, Gallo C, Siatì RDD, Spinato G, Filippis C de. Tinnitus following
281 COVID-19 vaccination: report of three cases. *Int J Audiol*. Published online June 13, 2021:1-
282 4. doi:10.1080/14992027.2021.1931969
- 283 4. Formeister EJ, Chien W, Agrawal Y, Carey JP, Stewart CM, Sun DQ. Preliminary Analysis
284 of Association Between COVID-19 Vaccination and Sudden Hearing Loss Using US Centers
285 for Disease Control and Prevention Vaccine Adverse Events Reporting System Data. *JAMA*
286 *Otolaryngol Head Neck Surg*. 07 01, 2021;147(7):674-676. doi:10.1001/jamaoto.2021.0869
- 287 5. Data. VAERS. Accessed October 1, 2021. <https://vaers.hhs.gov/data.html>
- 288 6. Viele K, Berry S, Neuenschwander B, et al. Use of historical control data for assessing
289 treatment effects in clinical trials. *Pharmaceutical Statistics*. 2014;13(1):41-54.
290 doi:<https://doi.org/10.1002/pst.1589>
- 291 7. FAQs. VAERS. Accessed September 14, 2021. <https://vaers.hhs.gov/faq.html>
- 292 8. Berlin JA, Glasser SC, Ellenberg SS. Adverse Event Detection in Drug Development:
293 Recommendations and Obligations Beyond Phase 3. *Am J Public Health*. 2008;98(8):1366-
294 1371. doi:10.2105/AJPH.2007.124537

COVID-19 Vaccines and Otologic Symptoms

- 295 9. Miller ER, McNeil MM, Moro PL, Duffy J, Su JR. The reporting sensitivity of the Vaccine
296 Adverse Event Reporting System (VAERS) for anaphylaxis and for Guillain-Barré syndrome.
297 *Vaccine*. 11 03, 2020;38(47):7458-7463. doi:10.1016/j.vaccine.2020.09.072
- 298 10. Su JR, Moro PL, Ng CS, Lewis PW, Said MA, Cano MV. Anaphylaxis after vaccination
299 reported to the Vaccine Adverse Event Reporting System, 1990-2016. *Journal of Allergy and*
300 *Clinical Immunology*. 2019;143(4):1465-1473. doi:10.1016/j.jaci.2018.12.1003
- 301 11. Neuhauser HK. Epidemiology of vertigo. *Current Opinion in Neurology*. 2007;20(1):40-46.
302 doi:10.1097/WCO.0b013e328013f432
- 303 12. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum
304 (Moderna COVID-19 Vaccine/mRNA-1273). Published December 18, 2020.
305 <https://www.fda.gov/media/144673/download>
- 306 13. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum
307 (Pfizer-BioNTech COVID-19 Vaccine/BNT162b2). Published December 11, 2020.
308 <https://www.fda.gov/media/144416/download>
- 309 14. FDA Emergency Use Authorization (EUA) for an Unapproved Product Review Memorandum
310 (Janssen COVID-19 Vaccine/Ad26.COV2.S). Published February 27, 2021.
311 <https://www.fda.gov/media/146338/download>
- 312 15. Ozonoff A, Nanishi E, Levy O. Bell's palsy and SARS-CoV-2 vaccines. *The Lancet Infectious*
313 *Diseases*. 2021;21(4):450-452. doi:10.1016/S1473-3099(21)00076-1
- 314 16. Martinez C, Wallenhorst C, McFerran D, Hall DA. Incidence Rates of Clinically Significant
315 Tinnitus: 10-Year Trend From a Cohort Study in England. *Ear and Hearing*. 2015;36(3):e69.
316 doi:10.1097/AUD.0000000000000121

COVID-19 Vaccines and Otologic Symptoms

- 317 17. Neuhauser HK, Radtke A, von Brevern M, Lezius F, Feldmann M, Lempert T. Burden of
318 Dizziness and Vertigo in the Community. *Arch Intern Med.* 2008;168(19):2118.
319 doi:10.1001/archinte.168.19.2118
- 320 18. Alexander TH, Harris JP. Incidence of sudden sensorineural hearing loss. *Otol Neurotol.*
321 2013;34(9):1586-1589. doi:10.1097/MAO.0000000000000222
- 322 19. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal
323 generation from spontaneous adverse drug reaction reports. *Pharmacoepidemiol Drug Saf.*
324 2001;10(6):483-486. doi:10.1002/pds.677
- 325 20. Almenoff JS, Pattishall EN, Gibbs TG, DuMouchel W, Evans SJW, Yuen N. Novel Statistical
326 Tools for Monitoring the Safety of Marketed Drugs. *Clinical Pharmacology & Therapeutics.*
327 2007;82(2):157-166. doi:<https://doi.org/10.1038/sj.clpt.6100258>
- 328 21. Eberth JM, Kline KN, Moskowitz DA, Montealegre JR, Scheurer ME. The Role of Media and
329 the Internet on Vaccine Adverse Event Reporting: A Case Study of Human Papillomavirus
330 Vaccination. *Journal of Adolescent Health.* 2014;54(3):289-295.
331 doi:10.1016/j.jadohealth.2013.09.005
332

COVID-19 Vaccines and Otologic Symptoms

333

VII. FIGURE LEGENDS

334 **Figure 1:** The Early-Onset Spike in VAERS Reports: All Adverse Events Reported to VAERS
335 for All Vaccines, COVID-19 and Non-COVID-19, Administered between December 14, 2020 and
336 June 7, 2021.

337 **Figure 2:** Triangle Venn Diagram Showing the Intersection of the Sets of Reports of Vertigo
338 (V), Tinnitus (T), and Hearing Loss (H) in VAERS data.

339 **Figure 3:** Spike Periods for Otologic Symptoms: Reports to VAERS of (a) Vertigo, (b)
340 Tinnitus, (c) Hearing Loss, and (d) Bell's Palsy in Relation to the COVID-19 Vaccines for Doses
341 Administered between December 14, 2020 and June 7, 2021, Showing Spike Periods During
342 Which Reported Cases Exceed Expected Cases. The solid line shows the number of cases reported
343 and the horizontal dashed line shows the expected number of cases based on the population
344 incidence rate. The vertical dotted line shows the number of days after dose administration at
345 which the spike of reported cases above expected cases ends. The vertical axis is labeled in report
346 numbers and the horizontal axis is labeled in the number of days between administration of the
347 dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an
348 underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case
349 counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts.

Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

| Table 1: Overview of the Data Used in the Study. | | |
|--|--|-----------------------------------|
| Study parameters | Period over which vaccinations included in the study were administered | December 14, 2020 to June 7, 2021 |
| | Days after vaccination observed | 30 |
| | Days after vaccination during which adverse event reports were collected | 60 |
| Vertigo¹ cases reported to VAERS (search term: “vertigo”) | Total cases | 3,993 |
| | mRNA-1273 | 1,713 |
| | BNT162b2 | 1,950 |
| | Ad26.COVS.S | 323 |
| Tinnitus² cases reported to VAERS (search terms: “tinnitus”; “hyposacusis”) | Total cases | 6,562 |
| | mRNA-1273 | 2,615 |
| | BNT162b2 | 3,366 |
| | Ad26.COVS.S | 573 |
| Hearing loss³ cases reported to VAERS (search terms: “hearing loss”; “deafness”; “hyposacusis”) | Total cases | 1,962 |
| | mRNA-1273 | 750 |
| | BNT162b2 | 1,036 |
| | Ad26.COVS.S | 170 |
| Bell’s palsy⁴ cases reported to VAERS (search terms: “bell’s palsy”; “facial palsy”; “facial paralysis”) | Total cases | 3,541 |
| | mRNA-1273 | 1,463 |
| | BNT162b2 | 1,824 |
| | Ad26.COVS.S | 248 |
| Overall vaccinated population (at least one dose)⁵ | Total | 171,310,738 |
| | mRNA-1273 | 69,355,687 |
| | BNT162b2 | 90,933,285 |
| | Ad26.COVS.S | 11,021,766 |

¹ Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in seven cases.

² Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in eight cases.

³ Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in six cases.

⁴ Cases by manufacturer do not sum to total cases because the vaccine manufacturer was not identified in six cases.

⁵ The manufacturer figures have been scaled to equal the total number of first-doses reported by the CDC to have been administered. It is not clear why the manufacturer figures reported by the CDC do not sum to the total without scaling.

Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

| Table 2: Comparing Spike Period Incidence Rates to General Population Incidence Rates. All incidence rates are annual per 100,000 persons. | | | |
|---|--|---|--|
| Symptom | Cases During Spike Period / Expected Cases for Spike Period / Spike Period (Days) | Incidence over Spike Period (95% CI) / General Population Incidence / Incidence over 21-Day Observation Period | z-statistic / p-value (two- tailed) / significant at the 95% confidence level? |
| Accuracy: 8%; Reporting Sensitivity/Multiplier: 30%/3.3 (vertigo: 0.6%/166.9); Overall: 28% (vertigo: 1,405%) | | | |
| Vertigo | 30,760.64 / 13,141.65 / 2 | 3,276.98 (3,240.96, 3,313.00) / 1,400 / 554.47 | 154.78 / <0.00001 / yes |
| Tinnitus | 972.94 / 506.89 / 2 | 103.65 (97.14, 110.16) / 54 / 18.06 | 20.71 / <0.00001 / yes |
| Hearing Loss | 185.07 / 126.72 / 1 | 39.43 (33.75, 45.11) / 27 / 5.34 | 5.18 / <0.00001/ yes |
| Bell’s Palsy | 346.06 / 215.90 / 2 | 36.87 (32.98, 40.75) / 23 / 9.27 | 8.86 / <0.00001 / yes |
| Accuracy: 8%; Reporting Sensitivity/Multiplier: 50%/2 (vertigo: 1%/100); Overall: 17% (vertigo: 845%) | | | |
| Vertigo | 18,503.71 / 13,141.65 / 2 | 1,971.23 (1,943.11, 1,999.35) / 1,400 / 333.53 | 47.11 / <0.00001 / yes |
| Tinnitus | 338.53 / 253.45 / 1 | 72.13 (64.45, 79.81) / 54 / 10.87 | 5.35 / <0.00001 / yes |
| Bell’s Palsy | 122.44 / 107.95 / 1 | 26.09 (21.47, 30.71) / 23 / 5.58 | 1.40 / 0.16 / no |
| Hearing Loss | No spike period; reported cases never exceed expected cases, suggesting the absence of a positive association between hearing loss and the COVID-19 vaccines. Incidence over a 21-day observation period is 3.21 per 100,000 person-years. | | |

Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

| Table 3: Proportional Reporting Ratios for Vertigo, Tinnitus, Hearing Loss, and Bell’s Palsy. | | | | | |
|---|---|---|--|--|--|
| Variable | (a) Cases after a COVID-19 vaccine dose | (b) Reports of all other adverse events after a COVID-19 vaccine dose | (c) Cases after all other non-COVID-19 vaccine doses | (d) Reports of all other adverse events after all other non-COVID-19 vaccine doses | PRR $\frac{\frac{a}{a+b}}{\frac{c}{c+d}}$ / χ^2 statistic (1 df) / p-value / significant at the 95% confidence level? |
| Vertigo | 3,993 | 458,837 | 9 | 4,955 | 4.76 / 14.13 / <0.001 / yes |
| Tinnitus | 6,562 | 456,268 | 13 | 4,951 | 5.41 / 19.48 / <0.0001 / yes |
| Hearing Loss | 1,962 | 460,868 | 8 | 4,956 | 2.63 / 2.66 / 0.103 / no |
| Bell’s Palsy | 3,541 | 459,289 | 26 | 4,938 | 1.46 / 0.21 / 0.65 / no |

Tables for “Preliminary Evidence of a Link between COVID-19 Vaccines and Otologic Symptoms”

| Table 4: Relative Incidence of Vertigo, Tinnitus, Hearing Loss, and Bell’s Palsy Associated with the mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. All incidence rates are annual per 100,000 persons. | | | | | |
|---|-------------|---|--|--|---|
| Accuracy: 8%; Reporting Sensitivity/Multiplier: 30%/3.3 (vertigo: 0.6%/166.9); Overall: 28% (vertigo: 1,405%) | | | | | |
| Adverse event | Vaccine | Cases During Spike Period / Total Recipients over Full Observation Period | Incidence over Spike Period / General Population Incidence | Comparison with mRNA-1273 Vaccine: z-statistic / p-value (two-tailed) / Significant at the 95% confidence level? | Comparison with BNT162b2 Vaccine: z-statistic / p-value (two-tailed) / Significant at the 95% confidence level? |
| Vertigo | mRNA-1273 | 13,434.07 / 69,355,687 | 3,534.99 / 1,400 | n/a | 15.50 / <0.00001 / yes |
| | BNT162b2 | 14,684.73 / 90,933,285 | 2,947.17 / 1,400 | n/i | n/a |
| | Ad26.COV2.S | 2,571.58 / 11,021,766 | 4,258.07 / 1,400 | 8.81 / <0.00001 / yes | 17.57 / <0.00001 / yes |
| Tinnitus | mRNA-1273 | 379.94 / 69,355,687 | 99.98 / 54 | n/a | 0.0 / 1.0 / no |
| | BNT162b2 | 497.53 / 90,933,285 | 99.85 / 54 | n/i | n/a |
| | Ad26.COV2.S | 94.63 / 11,021,766 | 156.70 / 54 | 3.88 / <0.001 / yes | 3.99 / <0.0001 / yes |
| Hearing Loss | mRNA-1273 | 63.28 / 69,355,687 | 33.30 / 27 | n/a | n/i |
| | BNT162b2 | 93.23 / 90,933,285 | 37.42 / 27 | 0.64 / 0.52 / no | n/a |
| | Ad26.COV2.S | 28.00 / 11,021,766 | 92.72 / 27 | 4.56 / <0.00001 / yes | 4.21 / <0.0001 / yes |
| “ | “ | “ | “ | “ | Comparison with Ad26.COV2.S Vaccine: . . . |
| Bell’ s Palsy | mRNA-1273 | 139.15 / 69,355,687 | 36.62 / 23 | n/a | 0.0 / 1.0 / no |
| | BNT162b2 | 184.51 / 90,933,285 | 37.03 / 23 | 0.04 / 0.96 / no | 0.05 / 0.96 / no |
| | Ad26.COV2.S | 21.56 / 11,021,766 | 35.70 / 23 | n/i | n/a |

Figure 1: The Early-Onset Spike in VAERS Reports: All Adverse Events Reported to VAERS for All Vaccines, COVID-19 and Non-COVID-19, Administered between December 14, 2020 and June 7, 2021.




Figure 2: Triangle Venn Diagram Showing the Intersection of the Sets of Reports of Vertigo (V), Tinnitus (T), and Hearing Loss (H) in VAERS data.





Figure 3:

Spike Periods for Otologic Symptoms: Reports to VAERS of (a) Vertigo, (b) Tinnitus, (c) Hearing Loss, and (d) Bell's Palsy in Relation to the COVID-19 Vaccines for Doses Administered between December 14, 2020 and June 7, 2021, Showing Spike Periods During Which Reported Cases Exceed Expected Cases.



The solid line shows the number of cases reported and the horizontal dashed line shows the expected number of cases based on the population incidence rate. The vertical dotted line shows the number of days after dose administration at which the spike of reported cases above expected cases ends. The vertical axis is labeled in report numbers and the horizontal axis is labeled in the number of days between administration of the dose and symptom onset. An accuracy discount rate of 8% has been applied to all case counts, an underreporting multiplier of 3.3 has been applied to the tinnitus, hearing loss, and Bell's palsy case counts, and an underreporting multiplier of 166.9 has been applied to the vertigo case counts.